Blog Posts

Razelle Kurzrock: An Abundance of Riches

Razelle Kurzrock/froedtert.com

Jul 5, 2025, 16:17

Razelle Kurzrock: An Abundance of Riches

Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories at Medical College of Wisconsin, shared a post on X:

“An abundance of riches. The number of anti-PD1 and anti-PDL1 agents keeps growing.

And they are amazing drugs.

Occasional they even cure refractory very advanced metastatic disease.”

More posts featuring Cancer Treatment.

anti-pd1 anti-PDL1 cancer cancer treatment OncoDaily Oncology Razelle Kurzrock

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Voices

Aug 18, 2025, 17:43

Building a Healthier Future for Women Also Means Building a Healthier Future for the Next Generation - Elekta Foundation

Voices

Aug 18, 2025, 17:35

Mandar Muzumdar: The Evolution of Single-Cell 3D Genomes in KRAS-Driven Cancers

Blog Posts

Aug 18, 2025, 17:21

Douglas Flora: Create the Things You Wish Existed

Blog Posts

Aug 18, 2025, 17:13

Matt Yurgelun: Thrilled to Be Joining The Jimmy Fund Radio-Telethon

Voices

Aug 18, 2025, 17:04

Striking out Cancer for Patients Like Charlie - The Jimmy Fund

Insight

Aug 18, 2025, 16:52

Darren Haywood: Pleased to Receive COSA Endorsement of the MASCC COG-IMPACT Tool

Science

Aug 18, 2025, 16:48

Petros Grivas: Highlighting Intra-Patient Tumor Heterogeneity in Prostate Cancer Research

Science

Aug 18, 2025, 16:46

How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? - Oncogene Cancer Research

Blog Posts

Aug 18, 2025, 16:37

Amanda Impellizzeri: What a Weekend at the Carolina Cancer Conference

Science

Aug 18, 2025, 16:33

Maria Tolia: New Study on Cardio-Oncology Considerations for Breast Cancer

Science

Aug 18, 2025, 16:25

The Findings from AICR and WCRF Research on World Breast Cancer Research Day

Voices

Aug 18, 2025, 16:10

Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio